MBX Biosciences, Inc. Common Stock

MBX

$61.52

+0.16%

2026-09-04 09:53:18 EDT+$0.10

Healthcare

Biotechnology

NASDAQ

Active Trading

MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic ...

Key Metrics of MBX

Snapshot

Latest / TTM · 5 periods

Market Cap

$2.92B

ROCE

-28.6%

EV / EBITDA

-26.63x

-2.1% YoY

FCF Yield

-2.9%

+4.2% YoY

Cash Conversion Cycle

-7097.9d

Current Ratio

18.08

Quick take

TTM —

No major risk flags in selected headline metrics.

Key Metrics

Latest / TTM · 5 periods

Valuation trend

Valuation trend table

Metric	2022	2023	2024	2025	TTM
Market CapTotal market value of all shares outstanding.	$753.34M	$753.34M	$615.43M	$1.15B	$2.92B
Enterprise ValueCompany value including debt and cash adjustments.	$729.59M	$723.14M	$566.25M	$1.08B	$2.87B
EV / SalesHow many dollars investors pay per dollar of sales.	0.00x	0.00x	0.00x	0.00x	0.00x
EV / EBITDAValuation multiple versus operating earnings before non-cash charges.	-28.38x	-22.32x	-9.18x	-12.42x	-26.63x
Net Debt / EBITDALeverage ratio using net debt divided by EBITDA.	0.92	0.93	0.80	0.86	0.47

Market-based metrics start from the IPO on 9/13/2024; earlier periods had no public share price.

Returns + ROCE gauge

ROCE latest

-28.6%

Prev year -26.5%

Returns + ROCE gauge table

Metric	2022	2023	2024	2025	TTM
ROEProfit generated from shareholders' equity.	61.3%	44.9%	-24.1%	-23.6%	-26.0%
ROAProfit generated from total assets.	-58.0%	-38.7%	-23.1%	-22.6%	-23.9%
ROICReturn generated on invested operating capital.	-61.9%	-40.6%	-24.1%	-23.6%	-26.3%
ROCEOperating return on long-term capital used.	-60.4%	-44.0%	-26.5%	-26.5%	-28.6%
Earnings YieldEarnings as a percentage of market value.	-3.5%	-4.3%	-10.1%	-7.6%	-3.6%

Cash flow quality

Cash flow quality table

Metric	2022	2023	2024	2025	TTM
FCFFCash flow available to all capital providers.	$-23.19M	$-32.11M	$-55.55M	$-81.88M	$-85.20M
FCFECash flow available to equity holders after debt flows.	$-13.56M	$-32.11M	$-55.55M	$-81.88M	$-85.20M
FCF YieldFree cash flow divided by market capitalization.	-3.1%	-4.3%	-9.0%	-7.1%	-2.9%
Income QualityHow well accounting earnings are backed by cash flow.	0.88	0.98	0.88	0.92	0.79
Capex / OCFShare of operating cash flow spent on capital expenditures.	-1.9%	-0.4%	-1.6%	-2.4%	-3.1%

Operating efficiency

Operating efficiency table

Metric	2022	2023	2024	2025	TTM
DSOAverage days to collect cash from customers.	0.0d	0.0d	0.0d	0.0d	0.0d
DIOAverage days inventory stays before being sold.	0.0d	0.0d	0.0d	0.0d	0.0d
DPOAverage days the company takes to pay suppliers.	0.0d	0.0d	0.0d	4381.5d	7097.9d
Operating CycleTime from buying inventory to collecting receivables.	0.0d	0.0d	0.0d	0.0d	0.0d
Cash Conversion CycleNet days cash is tied in operations.	0.0d	0.0d	0.0d	-4381.5d	-7097.9d

Snapshot

Latest / TTM: —

Market Cap

$2.92B

ROE

-26.0%

FCF Yield

-2.9%

Current Ratio

18.08

Upstream

Bachem Holding AGSWX:BANBPolyPeptide Group AGSWX:PPGNCordenPharma GmbHThermo Fisher Scientific Inc. (Patheon)NYSE:TMO Charles River Laboratories International, Inc.NYSE:CRL IQVIA Holdings Inc.NYSE:IQV ICON plcNASDAQ:ICLRIndiana University Research and Technology Corporation (IURTC)Merck KGaA (EMD Millipore)XETRA:MRKSigma-Aldrich (Merck KGaA / MilliporeSigma)XETRA:MRK

Downstream

Hypoparathyroidism Patient Population (Target End-Market)Post-Bariatric Hypoglycemia Patient Population (Target End-Market)Obesity/Metabolic Patient Population (Target End-Market)Ascendis Pharma A/SNASDAQ:ASND AstraZeneca PLCNASDAQ:AZNPotential Future Specialty Pharmacy Partners (e.g., CVS Specialty, Walgreens, Accredo)

Proxies

Ascendis Pharma A/SNASDAQ:ASNDBachem Holding AGSWX:BANBBridgeBio Pharma, Inc.NASDAQ:BBIO Rhythm Pharmaceuticals, Inc.NASDAQ:RYTM

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

No matching stocks found

MBX Biosciences, Inc. Common Stock

Key Metrics of MBX

Key Metrics

Valuation trend

Returns + ROCE gauge

Cash flow quality

Operating efficiency

Snapshot

Supply Chain of MBX

Upstream

Downstream

Proxies

Key Metrics of MBX

Key Metrics

Valuation trend

Returns + ROCE gauge

Cash flow quality

Operating efficiency

Snapshot

Supply Chain of MBX

Upstream

Downstream

Proxies